News

Penrhos Bio offers a novel, bioinspired solution to harmful biofilms. One step closer to self-cleaning surfaces

News

Unilever and Innova Partnerships one step closer to self-cleaning surfaces

Press Releases

January 5 2021

Unilever and Innova Partnerships one step closer
to self-cleaning surfaces

– Technology is based on seaweed, the ocean’s defence solution
– Launch of biotechnology company, Penrhos Bio, to scale anti-microbial solutions

5 January, 2020. London – Unilever and Innova Partnerships have launched a joint venture biotechnology company, Penrhos Bio, to commercialise a technology that means self-cleaning surfaces could become a reality.

The world first breakthrough has come with the introduction of an organic compound called Lactam which can block, or prevent, bacteria and mould on everyday surfaces.

Press Releases

January 5 2020

Unilever and Innova Partnerships one step closer to self-cleaning surfaces

– Technology is based on seaweed, the ocean’s defence solution
– Launch of biotechnology company, Penrhos Bio, to scale anti-microbial solutions

5 January, 2020. London – Unilever and Innova Partnerships have launched a joint venture biotechnology company, Penrhos Bio, to commercialise a technology that means self-cleaning surfaces could become a reality.
The world first breakthrough has come with the introduction of an organic compound called Lactam which can block, or prevent, bacteria and mould on everyday surfaces.

May 13 2020

This is a Headline

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar

May 13 2020

This is a Headline

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar

We are very proud that Penrhos Bio has been announced the winner in the prestigious Scotland Life Sciences Achievements Awards 2024 in the Innovative Collaboration Category. This reflects the highly successful partnership between Unilever, Penrhos and Pro3dure which has resulted in the new MSI technology (Multi Species Inhibition) for preventing harmful biofilms in 3d printed dental and audiology devices.

This is a three-way collaboration led by Penrhos Bio, with the R&D team in Unilever and our German partner Pro3dure. Pro3dure are word-leading as technical innovators in 3d printing for dental, audiology and medical fields. Combining their expertise with the passion to innovate, we have been able to collaborate with Pro3dure and Unilever to bring two new game-changing products to market in 2023 one a dental and one a hearing aid product. These will be forerunners of many more products to come incorporating the Remora technology and improving human health. Penrhos Bio works with world leading innovators in our key markets of which Pro3dure is a great example.

Mark Cook, Chair of the ILG expressed excitement about the outstanding quality of this year’s finalists, stating;
“Scotland’s Life Sciences Awards are a testament to the remarkable talent and innovation present in Scotland. The finalists have demonstrated exceptional dedication to their work, have redefined what is possible in our life sciences sector, and we are thrilled to acknowledge and celebrate their achievements at the Awards in March.”

The first 3d printed audiology device has been launched by our partners Pro3dure at the 67th Inter­na­tional Congress of Hearing Aid Acousti­cians hat benefits from th power of the Remora technology to inhibit biofilms.

This marks another milestone in the development of medical devices benefiting from Remora in the Multi Species Inhibition formulation developed by world experts in 3d medical printing Pro3dure, our licence partner in this field.

https://pro3dure-medical.com/media/pdf/f3/0a/69/MSI_Audio.pdf

Building on our announcement of the license deal in April, we are very pleased to announce a further advance in the use of the Remora technology in the medical space. Our partners Pro3dure have perfected the incorporation of their MSI technology (multi species inhibition) in the Audiology market. With over 5% of population of the world suffering from disabling hearing loss, and many more affected by partial loss, there is a growing need for safe effective and comfortable solutions to this problem. Hearing assist devices that are commonly used in the target population group (often over 65 years of age) are effective, but prolonged use of these devices may cause ear infections. For the first time there is now a 3D printed option offered by Pro3dure that matches the profile and ergonomics of the patients ear and offers the novel benefits from the incorporation of MSI technology. As with the dental devices, Pro3dure’s world leading expertise in 3d printing in medical devices has enabled a first to market solution. This is a rapidly growing sector reflecting market pull from an ageing global population and the drive to support quality of life in older age.

Working with our dental partners Pro3dure Medical, our anti biofilm platform (Remora™) has been incorporated into two of their key medical devices using their MSI® (Multi Species Inhibition) technology. We are delighted to announce that Health Canada have now reviewed and granted licenses for these medical devices. This is a great milestone for Penrhos Bio and further indication of the confidence in the Remora technology.

Congratulations to our partners in Pro3dure and to our licence partner and Key Opinion Leader in the dental space Dr Gary Jernberg, who has been instrumental in this partnership.

Building on early success in the field of dental implants, Penrhos Bio has extended our presence in the medical device market with a first license in audiology, for 3D printed hearing aids.

With the huge technological and material advances in 3D printing, it is now possible to produce comfortable custom hearing aids quickly and cost-effectively. The market is growing and although estimates of 3D printed hearing aids in use were 10 million in 2021, this is expanding rapidly with clear benefits to the customer based on new innovations.

The Remora technology compliments these advances by helping keep the device hygienically clean. Our partners in Pro3dure Medical have world leading expertise in the 3D printing of medical devices and Penrhos Bio are therefore pleased to announce that we have signed a further licence with Pro3dure to incorporate our Remora technology in their novel resins for hearing aids.

Further Information 

https://www.pro3dure.com/en/

https://www.pro3dure.com/en/

First product launched with Remora® technology to control harmful biofilms at IDS dental trade fare, Germany

Today at the IDS dental trade fare in Cologne, Pro3dure Medical GmbH have launched a 3D printable polymer containing Remora® for use in the construction of dental reliners that helps control harmful biofilms.

The PrintoDent® GR-10 resin incorporated with RemoraR is being made available for use in 3D printed dental liners and dental blanks. The 3D printable dental market is estimated to be worth $3.2 billion in 2022 and is growing at 20.2% CAGR from 2022-2027.

Commenting, Dr Yvonne Davies, Head of Business Development for Penrhos Bio Ltd said ‘We announced our collaboration with Pro3dure Medical in 2022 and the team have done a great job incorporating RemoraR into their 3D printable resins. We look forward to commercial success across our divisions during 2023.’

Dr Martin Klare, CEO of Pro3dure Medical said ‘What Remora® offers us is a unique and patented approach to controlling harmful biofilms. Applying this in our Multi-Species Inhibition (MISR) product range allows us to offer our functional 3D printed dental materials.’

Remora® is inspired by the natural biology of the oceans and helps keep surfaces cleaner for longer. The technology has been developed over many years in Unilever and was recently licensed exclusively to Penrhos Bio Ltd for wider commercialisation beyond homecare applications.

Further Information 

https://www.pro3dure.com/en/

https://www.pro3dure.com/en/

Penrhos Bio is currently undertaking a Series A investment raise. This investment will accelerate our regulatory roadmap for the Remora™ technology and unlocks a number of higher value markets such as marine fouling and human healthcare. It also empowers our commercial partners to fully leverage the value of the technology in their products, opening new opportunities and segments.

We will be closing this round in the first half of 2023. If you interested in joining us as an investment partner, please contact our Chief Commercial Officer, Dr Steve Howell; cco@remora.bio

Penrhos Bio: Winners in the prestigious Scotland Life Sciences Achievements Awards 2024!

We are very proud that Penrhos Bio has been announced the winner in the prestigious Scotland Life Sciences Achievements Awards 2024 in the Innovative Collaboration Category. This reflects the highly successful partnership between Unilever, Penrhos and Pro3dure which has resulted in the new MSI technology (Multi Species Inhibition) for preventing harmful biofilms in 3d printed […]

First Audiology Product Launched incorporating Remora™

The first 3d printed audiology device has been launched by our partners Pro3dure at the 67th Inter­na­tional Congress of Hearing Aid Acousti­cians hat benefits from th power of the Remora technology to inhibit biofilms. This marks another milestone in the development of medical devices benefiting from Remora in the Multi Species Inhibition formulation developed by […]

Health Canada approve Remora™ technology in two medical devices.

Working with our dental partners Pro3dure Medical, our anti biofilm platform (Remora™) has been incorporated into two of their key medical devices using their MSI® (Multi Species Inhibition) technology. We are delighted to announce that Health Canada have now reviewed and granted licenses for these medical devices. This is a great milestone for Penrhos Bio […]
Penrhos Bio joins with Pro3dure™ in a milestone licence deal that will bring the Remora™ technology into the dental space in 3D printed materials...
Penrhos Bio joins with Pro3dure™ in a milestone licence deal that will bring the Remora™ technology into the dental space in 3D printed materials...
Penrhos Bio is currently undertaking a Series A investment raise. This investment will accelerate our regulatory roadmap for the Remora™ technology and unlocks a number of higher value markets such as marine fouling and human healthcare...
Penrhos Bio joins with Pro3dure™ in a milestone licence deal that will bring the Remora™ technology into the dental space in 3D printed materials...
Thanks to our Partners in Earthbound Brands, Remora™ becomes our brand name, logo and the face of Penrhos Bio. Supported by the ‘Cleaner by Nature’ tagline, the new Remora name will flow though onto products in our customers hands...
Penrhos Bio raise £1m Seed funding to accelerate development of the Remora™️ technology and is joined as an investment partner by Eos Advisory...
Penrhos Bio has become a member of the National Biofilms Innovation Centre, a world leading Innovation Knowledge Centre connecting scientists and industrial partners specialising in Biofilms from across the UK...
Dental plaque is an example of a typical biofilm composed of a complex microbial community. Plaque is the contributing agent for major dental diseases such as dental caries and periodontal disease...
We are very pleased that Dr Yvonne Davies and Professor Richard Hammond have joined Penrhos Bio full time. Yvonne is Head of Business development and Richard is CEO...